[{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ChromaDex Announces New Clinical Trial to Investigate Niagen\u00ae and Milk Production Among Mothers in the Neonatal Intensive Care Unit (NICU)","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ChromaDex's NRC Gets FDA ODD and RPD for Ataxia Telangiectasia","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2024","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical"}]
Find Clinical Drug Pipeline Developments & Deals for Nicotinamide Riboside Chloride
Niagen (nicotinamide riboside chloride) is an oral supplement which significantly increases NAD+ levels, it is being investigated in Ataxia Telangiectasia.
ChromaDex has invested over $35 million in investigating and marketing NR as Niagen, which has received regulatory acceptance in the United States, Canada, the European Union, and Australia.